News

For over one hundred years, we have believed in all types of innovation, from market trends and new client products and services … Meet our new visual identity!

As part of its Social Responsibility Program, Kasznar Leonardos donated over 700 packages of basic foodstuffs through the “Gramachinhos” Project in Rio … Kasznar Leonardos donates basic foodstuffs to families in Rio de Janeiro and Sao Paulo

In May 2020, Kasznar Leonardos implemented its Diversity and Inclusion Program aiming to create a more inclusive work environment. Over the past … Kasznar Leonardos celebrates the first year of its Diversity & Inclusion Program

Kasznar Leonardos is pleased to announce the promotion of three new partners, effective January 2021. Ísis Valaziane and Luciana Minada will become … New partners for Litigation and Patents

Based in New York City, Marcel will help strengthen our capabilities in the US and Asian markets by helping our clients to … Kasznar Leonardos welcomes Marcel Nadal Michelman as our Of Counsel in the USA

With more than 20 years' experience in legal and intellectual property areas, Maria Pia Guerra has joined our firm as Executive Director of our international unit I’B The IP Hub

Rosane Tavares has more than 30 years' experience in Intellectual Property.

On April 17, 2018 the Superior Court of Justice had the opportunity to analyze the first Special Appeal addressing the term of … Brazilian Superior Court of Justice decides its first mailbox case

In a decision made available on the 7th of November, Judge of the Supreme Court Luiz Fux dismissed a lawsuit by which … Supreme Court dismisses lawsuit against rule that guarantees a minimum term for patent protection

On August 8 2017 ANVISA officially published the new Rule RDC Nº 168, related to the prior consent of the Agency on patent applications for pharmaceutical products and processes, regulated by Joint Ordinance ANVISA-INPI No. 1, dated April 12, 2017, aiming to a more efficient way to analyze patent applications.

ANVISA has published, on 08/02/2017, in the Federal Register, the the Public Consultation 371/2017 to discuss the extension, from 5 to 10 … Medical Devices – ANVISA´s Public Consultation to extend the registration term

The Ministry of Industry and Commerce (MDIC) and the Brazilian Patent and Trademark Office (INPI) have opened for Public Consultation a Proposal for a Resolution to regulate a simplified allowance procedure for patent applications in Brazil, aiming to deal in a swift manner with the ever increasing backlog of patent applications awaiting examination, currently exceeding the figure of 230.000.

The Ministry of Industry and Commerce (MDIC) and the Brazilian Patent and Trademark Office (INPI) have opened for Public Consultation a Proposal for a Resolution to regulate a simplified allowance procedure for patent applications in Brazil, aiming to deal in a swift manner with the ever increasing backlog of patent applications awaiting examination, currently exceeding the figure of 230.000.

Allergan had obtained an injunction preventing the marketing of a generic drug for Combingan®. However, such injunction was revoked because the Trial … São Paulo Court allows the marketing of generic drug while the patent applications for the reference drug are still pending

ANVISA has informed in its website, on 07/04/2017, the undertake of an operation that determined the shutdown, for at least 30 days, of a manufacturing line of personalized face and skull prostheses.
According to ANVISA, the Senai Joinville (a branch of the National Industrial Apprentice Service) has been manufacturing customized prostheses without authorization of the regulatory agency.